SUN 1334H

Drug Profile

SUN 1334H

Alternative Names: SUN 1334; SUN-1334H

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Sun Pharmaceutical Industries
  • Class Antiallergics; Antihistamines
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic conjunctivitis; Perennial allergic rhinitis; Seasonal allergic rhinitis; Urticaria

Most Recent Events

  • 24 Aug 2011 Phase-I/II clinical trials in Perennial allergic rhinitis in India (Intranasal)
  • 24 Aug 2011 Phase-I/II clinical trials in Seasonal allergic rhinitis in India (Intranasal)
  • 30 Jun 2011 Phase-II clinical trials in Allergic conjunctivitis in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top